Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that colonizes the human stomach, leading to chronic inflammation and significant gastrointestinal diseases such as peptic ulcers and gastric adenocarcinoma (StatPearls, 2023). The target "Multiple H. pylori proteins and surface structures" refers to a collective group of bacterial components essential for its survival in the acidic gastric environment and its ability to cause disease. Key components include the enzyme urease, which neutralizes stomach acid by producing ammonia, and virulence factors such as Cytotoxin-associated gene A (CagA) and Vacuolating cytotoxin A (VacA) that disrupt host cellular processes and induce apoptosis (Amieva & Peek, 2016). Surface structures like flagella enable motility through the mucus layer, while adhesins such as Blood group antigen-binding adhesin (BabA) facilitate attachment to gastric epithelial cells (NCBI, 2022). Current therapeutic strategies utilize a combination of antibiotics, such as amoxicillin and clarithromycin, which target bacterial cell wall synthesis and protein synthesis respectively, often in conjunction with acid-suppressing agents (Chey et al., 2017). This multi-target approach is critical for effective eradication, although rising antibiotic resistance remains a major therapeutic challenge (Malfertheiner et al., 2022).
Inhibition of bacterial cell wall synthesis, inhibition of protein synthesis via 50S or 30S ribosomal subunits, inhibition of DNA gyrase, and disruption of DNA helical structure.
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Helicobacter pylori proteins and surface structures (H. pylori targets).